Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer

Y Tomita, T Ikeda, S Sakata, K Saruwatari, R Sato… - Cancer immunology …, 2020 - AACR
Gut dysbiosis caused by antibiotics impairs response to immune checkpoint blockade (ICB).
Gut microbiota is becoming an attractive therapeutic target for cancer. The Clostridium …

Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors

Y Tomita, Y Goto, S Sakata, K Imamura… - …, 2022 - Taylor & Francis
Oral microbiota is associated with human diseases including cancer. Emerging evidence
suggests that proton pump inhibitors (PPIs), which allow the oral microbiome to translocate into …

[HTML][HTML] Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI …

Y Sakata, S Sakata, Y Oya, M Tamiya, H Suzuki… - European Journal of …, 2021 - Elsevier
Background Osimertinib is the standard of care in the initial treatment for advanced epidermal
growth factor receptor (EGFR) mutation–positive lung cancer. However, clinical data and …

[HTML][HTML] Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer …

K Tanaka, K Nosaki, K Otsubo, K Azuma, S Sakata… - Oncotarget, 2017 - ncbi.nlm.nih.gov
The T790M secondary mutation of the epidermal growth factor receptor (EGFR) gene
accounts for 50% to 60% of cases of resistance to the first-generation EGFR tyrosine kinase …

Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L

S Sakata, K Otsubo, H Yoshida, K Ito… - Cancer …, 2022 - Wiley Online Library
Considering the increasing number of identified driver oncogene alterations, additional
genetic tests are required to determine the treatment for advanced non‐small‐cell lung cancer (…

[HTML][HTML] Disorder of coagulation-fibrinolysis system: an emerging toxicity of anti-PD-1/PD-L1 monoclonal antibodies

R Sato, K Imamura, S Sakata, T Ikeda, Y Horio… - Journal of clinical …, 2019 - mdpi.com
A disruption of immune checkpoints leads to imbalances in immune homeostasis, resulting
in immune-related adverse events. Recent case studies have suggested the association …

[HTML][HTML] Psb28 is involved in recovery of photosystem II at high temperature in Synechocystis sp. PCC 6803

S Sakata, N Mizusawa, H Kubota-Kawai… - … et Biophysica Acta (BBA …, 2013 - Elsevier
Psb28 is an extrinsic protein of photosystem II (PSII), which is conserved among
photosynthetic organisms from cyanobacteria to higher plants. A unicellular cyanobacterium, …

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non‐small‐cell lung cancer

…, CK Imamura, H Ogata, A Fujita, S Sakata… - Cancer …, 2017 - Wiley Online Library
Spliced variant isoforms of CD 44 ( CD 44v) are a marker of cancer stem cells in solid tumors.
They stabilize the xCT subunit of the transporter system xc(–) and thereby promote …

Drug-related pneumonitis induced by osimertinib as first-line treatment for epidermal growth factor receptor mutation-positive non-small cell Lung Cancer: a real-world …

Y Sato, H Sumikawa, R Shibaki, T Morimoto, Y Sakata… - Chest, 2022 - Elsevier
Background Osimertinib has demonstrated impressive efficacy as a first-line treatment for
patients with advanced epidermal growth factor receptor (EGFR) mutation-positive (m+) lung …

[HTML][HTML] Histologic transformation of epidermal growth factor receptor–mutated lung cancer

…, A Hata, H Suzuki, H Matsumoto, S Sakata… - European Journal of …, 2022 - Elsevier
Purpose This study aimed to determine the incidence and clinical course of epidermal growth
factor receptor (EGFR)-mutated lung cancer with histologic transformation (HT). Patients …